Literature DB >> 21415357

Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.

Philip E Castle1, Ruth Shaber, Brandon J LaMere, Walter Kinney, Barbara Fetterma, Nancy Poitras, Thomas Lorey, Mark Schiffman, Anne Dunne, Janae M Ostolaza, Sharod McKinney, Robert D Burk.   

Abstract

BACKGROUND: The human papillomavirus (HPV) Persistence and Progression Cohort is a natural history study of carcinogenic HPV positive women. Here, we present the HPV genotypes found in first ∼500 cases of cervical intraepithelial neoplasia grade 3 (CIN3) or more severe disease (CIN3+) diagnosed at the study baseline.
METHODS: Women aged 30 and older were screened for cervical cancer using Pap smears and tested for carcinogenic HPV using Hybrid Capture 2 (HC2; Qiagen). We randomly selected women who tested HPV positive and were diagnosed with CIN3+ (n = 448) or without CIN3+ (<CIN3; n = 830). Residual cervical Pap specimens were HPV genotyped using a MY09/11 L1-targeted PCR method.
RESULTS: Among HC2-positive women, HPV16 (48.9%), HPV31 (9.2%), and HPV18 (8.5%) were the most common HPV genotypes in CIN3+. There was a decrease at older ages in the fraction of CIN3 (P(trend) = 0.006), adenocarcinoma in situ (AIS) (P(trend) = 0.08), and CIN3/AIS (P(trend) = 0.002) associated with HPV16. Compared to the other carcinogenic HPV genotypes in aggregate, HPV18 was strongly associated with CIN3+ in women with a normal Pap [odds ratio (OR) = 5.7, 95% CI = 1.2-26] but not in women with abnormal Pap (OR = 1.3, 95% CI = 0.74-2.3).
CONCLUSIONS: HPV16 is more strongly associated with cervical precancer diagnosed in younger women (vs. older women). HPV18 infections were linked to precancerous lesions that were missed by cytology. IMPACT: The progression timeline of HPV16 differs from other carcinogenic HPV genotypes, which may impact the use of HPV16 detection in the management of HPV-positive women. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415357      PMCID: PMC3117227          DOI: 10.1158/1055-9965.EPI-10-1267

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

1.  Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort.

Authors:  Brandon J LaMere; Janet Kornegay; Barbara Fetterman; Mark Sadorra; Jen Shieh; Philip E Castle
Journal:  J Virol Methods       Date:  2007-07-27       Impact factor: 2.014

2.  Heterogeneity in CIN3 diagnosis.

Authors:  Mark Schiffman; Ana Cecilia Rodríguez
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

3.  Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women.

Authors:  Carolina Porras; Ana Cecilia Rodríguez; Allan Hildesheim; Rolando Herrero; Paula González; Sholom Wacholder; Robert D Burk; Mark Schiffman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03       Impact factor: 4.254

4.  Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping.

Authors:  Brandon J LaMere; Renee Howell; Barbara Fetterman; Jen Shieh; Philip E Castle
Journal:  J Virol Methods       Date:  2008-06-24       Impact factor: 2.014

5.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Authors:  N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer
Journal:  Lancet       Date:  2007-10-04       Impact factor: 79.321

6.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

Review 7.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Authors:  Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2008-05-15       Impact factor: 4.897

8.  Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma.

Authors:  Nicolas Wentzensen; Mark Schiffman; S Terence Dunn; Rosemary E Zuna; Joan Walker; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Jose Jeronimo; Michael A Gold; Sophia S Wang
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

9.  Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting.

Authors:  Philip E Castle; Barbara Fetterman; Nancy Poitras; Thomas Lorey; Ruth Shaber; Walter Kinney
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.623

10.  Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Authors:  Cosette M Wheeler; William C Hunt; Nancy E Joste; Charles R Key; Wim G V Quint; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

View more
  25 in total

1.  Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Authors:  Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-02       Impact factor: 4.254

2.  Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Authors:  Megan A Clarke; Ana Gradissimo; Nicolas Wentzensen; Robert D Burk; Mark Schiffman; Jessica Lam; Christopher C Sollecito; Barbara Fetterman; Thomas Lorey; Nancy Poitras; Tina R Raine-Bennett; Philip E Castle
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

3.  A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.

Authors:  M Schiffman; R D Burk; S Boyle; T Raine-Bennett; H A Katki; J C Gage; N Wentzensen; J R Kornegay; C Aldrich; T Tam; H Erlich; R Apple; B Befano; P E Castle
Journal:  J Clin Microbiol       Date:  2014-10-22       Impact factor: 5.948

4.  Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.

Authors:  Maria Demarco; Olivia Carter-Pokras; Noorie Hyun; Philip E Castle; Xin He; Cher M Dallal; Jie Chen; Julia C Gage; Brian Befano; Barbara Fetterman; Thomas Lorey; Nancy Poitras; Tina R Raine-Bennett; Nicolas Wentzensen; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

5.  The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.

Authors:  Mark Schiffman; Sean Boyle; Tina Raine-Bennett; Hormuzd A Katki; Julia C Gage; Nicolas Wentzensen; Janet R Kornegay; Raymond Apple; Carrie Aldrich; Henry A Erlich; Thanh Tam; Brian Befano; Robert D Burk; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-18       Impact factor: 4.254

6.  Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3.

Authors:  Nicolas Wentzensen; Chang Sun; Arpita Ghosh; Walter Kinney; Lisa Mirabello; Sholom Wacholder; Ruth Shaber; Brandon LaMere; Megan Clarke; Attila T Lorincz; Philip E Castle; Mark Schiffman; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2012-10-23       Impact factor: 13.506

7.  HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women.

Authors:  Lisa Mirabello; Meredith Yeager; Michael Cullen; Joseph F Boland; Zigui Chen; Nicolas Wentzensen; Xijun Zhang; Kai Yu; Qi Yang; Jason Mitchell; David Roberson; Sara Bass; Yanzi Xiao; Laurie Burdett; Tina Raine-Bennett; Thomas Lorey; Philip E Castle; Robert D Burk; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2016-04-29       Impact factor: 13.506

8.  HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer.

Authors:  Lisa Mirabello; Marina Frimer; Ariana Harari; Thomas McAndrew; Benjamin Smith; Zigui Chen; Nicolas Wentzensen; Sholom Wacholder; Philip E Castle; Tina Raine-Bennett; Mark Schiffman; Robert D Burk
Journal:  Int J Cancer       Date:  2014-09-03       Impact factor: 7.396

9.  HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.

Authors:  Lisa Mirabello; Meredith Yeager; Kai Yu; Gary M Clifford; Yanzi Xiao; Bin Zhu; Michael Cullen; Joseph F Boland; Nicolas Wentzensen; Chase W Nelson; Tina Raine-Bennett; Zigui Chen; Sara Bass; Lei Song; Qi Yang; Mia Steinberg; Laurie Burdett; Michael Dean; David Roberson; Jason Mitchell; Thomas Lorey; Silvia Franceschi; Philip E Castle; Joan Walker; Rosemary Zuna; Aimée R Kreimer; Daniel C Beachler; Allan Hildesheim; Paula Gonzalez; Carolina Porras; Robert D Burk; Mark Schiffman
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

10.  Genetic and Epigenetic Variations of HPV52 in Cervical Precancer.

Authors:  Katharine J Bee; Ana Gradissimo; Zigui Chen; Ariana Harari; Mark Schiffman; Tina Raine-Bennett; Philip E Castle; Megan Clarke; Nicolas Wentzensen; Robert D Burk
Journal:  Int J Mol Sci       Date:  2021-06-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.